| 2.4 -0.01 (-0.41%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.2 | 1-year : | 3.73 |
| Resists | First : | 2.74 | Second : | 3.2 |
| Pivot price | 2.43  |
|||
| Supports | First : | 2.26 | Second : | 1.96 |
| MAs | MA(5) : | 2.42 | MA(20) : | 2.47 |
| MA(100) : | 2.84 |
MA(250) : | 3.62 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.7 |
D(3) : | 59.9 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 12 | Low : | 1.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LIPO ] has closed above bottom band by 39.6%. Bollinger Bands are 68.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.44 - 2.46 | 2.46 - 2.47 |
| Low: | 2.36 - 2.38 | 2.38 - 2.4 |
| Close: | 2.37 - 2.4 | 2.4 - 2.42 |
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Tue, 08 Apr 2025
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus - GlobeNewswire
Tue, 08 Apr 2025
Clinical Trial Success: Lipella's Novel OLP Treatment Shows Encouraging Results in Phase 2a Study - Stock Titan
Mon, 31 Mar 2025
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast - GlobeNewswire
Mon, 31 Mar 2025
Clinical Trial Success: Lipella's 40-Year Veteran Shares Breakthrough Journey in Exclusive Interview - Stock Titan
Tue, 04 Mar 2025
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement - Yahoo Finance
Tue, 11 Feb 2025
Clinical Trial Success: Lipella's LP-310 Slashes Pain Scores by 64% in Oral Disease Study - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 9 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 56 (K) |
| Shares Short P.Month | 216 (K) |
| EPS | -4.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | 0 % |
| Operating Margin | -835.7 % |
| Return on Assets (ttm) | -101.6 % |
| Return on Equity (ttm) | -198.2 % |
| Qtrly Rev. Growth | 43.7 % |
| Gross Profit (p.s.) | -1.21 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.51 |
| PEG Ratio | 0 |
| Price to Book value | 1.5 |
| Price to Sales | 11.41 |
| Price to Cash Flow | -1.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|